Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orlistat

A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)

Empros Pharma AB · Phase 1/2 · Completed · Enrollment 156

NCT04521751

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
EMP16-02 120 mg orlistat/40 mg acarbosen/rn/rn/rn/r
EMP16-02 150 mg orlistat/50 mg acarbosen/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • EMP16-02 120 mg orlistat/40 mg acarbose: endpoint not reported
  • EMP16-02 150 mg orlistat/50 mg acarbose: endpoint not reported
  • Placebo: endpoint not reported